Aeglea BioTherapeutics buys Spyre Therapeutics to revolutionize IBD treatment

Aeglea BioTherapeutics, a Nasdaq-listed company, has acquired Spyre Therapeutics, a private biotech company dedicated to advancing a promising pipeline of antibody therapeutics aimed at revolutionizing ... Read More